16548-07-5

Usage

Uses

Used in Pharmaceutical Industry:
Ethylsulfamoyl chloride is used as a reagent in the preparation of flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease. It plays a crucial role in the synthesis of these therapeutic agents, which can help manage and prevent the spread of the hepatitis B virus.
Used in Organic Synthesis:
Ethylsulfamoyl chloride is used as a versatile building block in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals. Its reactivity allows for the formation of a wide range of products, making it a valuable tool in the field of organic chemistry.

Synthesis Reference(s)

The Journal of Organic Chemistry, 41, p. 4028, 1976 DOI: 10.1021/jo00887a022

Upstream product

• 4626-94-2 ethylaminosulfonic acid 
• 557-66-4 ethanamine hydrochloride 
• 7791-25-5 sulfuryl dichloride 
• 75-04-7 ethylamine 

Downstream Products

• 57836-29-0 Ethyl-sulfamic acid [(2,6-dimethyl-phenyl)-propoxymethyl-carbamoyl]-methyl ester 
• 57836-27-8 Ethyl-sulfamic acid [(2,6-dimethyl-phenyl)-ethoxymethyl-carbamoyl]-methyl ester 
• 57836-35-8 Ethyl-sulfamic acid [(2,6-diethyl-phenyl)-methoxymethyl-carbamoyl]-methyl ester 
• 57836-32-5 Ethyl-sulfamic acid [(2,6-dimethyl-phenyl)-isopropoxymethyl-carbamoyl]-methyl ester 
• 26118-79-6 N-Aethyl-amidosulfonsaeure-thiophenylester 
• 70484-55-8 2-morpholin-4-yl-1,3-diphenyl-prop-2-ene-1-sulfonic acid ethylamide 
• 26120-06-9 N-Aethyl-N'-phenyl-sulfonyldiamid 
• 70484-59-2 2-morpholin-4-yl-1,2-diphenyl-ethenesulfonic acid ethylamide 
• 80-39-7 N-ethyl-4-methyl-benzenesulfonamide 
• 96855-43-5 2-Oxo-cyclohexanesulfonic acid ethylamide 
• 936213-89-7 (C₆H₅)3CSC₄H₆NCO₂CH₂CHCH₂CNOCH₃CH₂NHSO₂NHCH₂CH₃ 

Relevant academic research and scientific papers

PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH

The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.

Development of CINPA1 analogs as novel and potent inverse agonists of constitutive androstane receptor

Constitutive androstane receptor (CAR, NR1I3) and pregnane X receptor (PXR, NR1I2) are master regulators of endobiotic and xenobiotic metabolism and disposition. Because CAR is constitutively active in certain cellular contexts, inhibiting CAR might reduce drug-induced hepatotoxicity and resensitize drug-resistant cancer cells to chemotherapeutic drugs. We recently reported a novel CAR inhibitor/inverse agonist CINPA1 (11). Here, we have obtained or designed 54 analogs of CINPA1 and used a time-resolved fluorescence resonance energy transfer (TR-FRET) assay to evaluate their CAR inhibition potency. Many of the 54 analogs showed CAR inverse agonistic activities higher than those of CINPA1, which has an IC50 value of 687 nM. Among them, 72 has an IC50 value of 11.7 nM, which is about 59-fold more potent than CINPA1 and over 10-fold more potent than clotrimazole (an IC50 value of 126.9 nM), the most potent CAR inverse agonist in a biochemical assay previously reported by others. Docking studies provide a molecular explanation of the structure-activity relationship (SAR) observed experimentally. To our knowledge, this effort is the first chemistry endeavor in designing and identifying potent CAR inverse agonists based on a novel chemical scaffold, leading to 72 as the most potent CAR inverse agonist so far. The 54 chemicals presented are novel and unique tools for characterizing CAR's function, and the SAR information gained from these 54 analogs could guide future efforts to develop improved CAR inverse agonists.

SELECTIVE INHIBITORS OF CONSTITUTIVE ANDROSTANE RECEPTOR

The compounds of the invention are antagonists of CAR, with specificity for CAR over other proteins including PXR. The disclosed compounds are useful in treating or controlling cell proliferative disorders, in particular oncological disorders, such as cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Sulfamates as antiglaucoma agents

Sulfamate esters of the formula where A is aryloxyalkyl, p is the number of unreacted hydroxy groups present on the alkyl moiety and may be zero, z is the number of --OS(O)2 NR1 R2 groups attached to carbons of the alkyl moiety and is always at least one; R1 and R2 are selected from hydrogen, loweralkyl, carboxy, and the like are useful in treating glaucoma.

Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals

Methods of treating chronic arthritis and osteoporosis which utilize both known and novel compounds which would fall under the general formula:(HO)p--A--[--OS(O) 2 NR 1 R 2 ] zwherein A encompasses a wide range of values including but not limited to aryl, loweralkyl, cycloalkyl, and carbohydrates including sucrose and fructose; p is equal to the number of unreacted hydroxy groups contained on the molecule and may be zero; z is the number of --OS(O) 2 NR 1 R 2 groups and is always at least one; R 1 and R 2 are selected from hydrogen, loweralkyl, carboxy and the like; a novel process for preparing the compounds is provided wherein an appropriate sulfamic acid aryl ester is reacted with a hydroxy substituted A radical which may or may not contain thereon protected carboxyl, amino or hydroxy substituents, in an aprotic solvent containing a tertiary amine base. Pharmaceutical compositions for the treatment of chronic arthritis and osteoporosis are also provided.

Preparation of sulfamyl halides

Sulfamyl halides are prepared by reacting sulfamic acids with halogen in the presence of phosphorus or of a phosphorus trihalide; the sulfamic acid can first be prepared from an isocyanate or urea and then be reacted as above in a one-vessel method. The compounds obtainable by the process of the invention are valuable starting materials for the preparation of crop protection agents, dyes and drugs.

N-pyrazinecarbonyl-N'-substituted-sulfamoylguanidine and processes for preparing same

The case involves novel N-pyrazinecarbonyl-N'-substituted-sulfamoylguanidine and processes for preparing same. The N-pyrazinecarbonyl-N'-substituted-sulfamoylguanidines are excellent eukalemic agents possessing diuretic and natriuretic properties.